本研究针对MYBPC3相关肥厚型心肌病（HCM）这一缺乏有效治疗方案的疾病，开展了首次人体试验MyPEAK-1，评估AAV9基因替代疗法TN-201的安全性与有效性。结果显示，单次给药后心肌肌球蛋白结合蛋白C（MyBP-C）水平提升，心脏生物标志物改善，左心室肥厚指标减轻，且 ...

We studied 307 CML patients: 42 had extramedullary MS and a history of or concurrent CML in the bone marrow (BM), and 265 had medullary myeloid BP (MyBP) but without previous or concurrent MS. All ...

Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy ...

Tenaya Management to Host Webcast Call for Analysts and Investors on Monday, November 10 at 8:00 a.m. EST TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic ...